• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

艰难梭菌感染的医疗资源利用和可归因成本:比较首次和复发性发作的微观成本分析。

Healthcare resource use and attributable cost of Clostridium difficile infection: a micro-costing analysis comparing first and recurrent episodes.

机构信息

Department of Paediatric Infectious Diseases, Evelina Children's Hospital, Guy's & St Thomas' NHS Foundation Trust, London, UK.

Centre for Clinical Infection and Diagnostics Research, King's College London and Guy's & St Thomas' NHS Foundation Trust, London, UK.

出版信息

J Antimicrob Chemother. 2018 Oct 1;73(10):2851-2855. doi: 10.1093/jac/dky250.

DOI:10.1093/jac/dky250
PMID:29982502
Abstract

OBJECTIVES

Accurate and sufficiently detailed data on the economic burden of Clostridium difficile infection (CDI) are lacking. We performed a micro-costing study to determine the health resource utilization of patients with a first episode of CDI (fCDI) and those with a recurrent episode of CDI (rCDI).

PATIENTS AND METHODS

Forty-five adult and paediatric inpatients with rCDI were matched by age, sex and date of diagnosis with control patients with fCDI. Total length of hospital stay, length of stay in the ICU and several cost parameters differentiated into fixed and variable components were measured and compared across both groups.

RESULTS

The mean total length of stay for rCDI patients was 33 days (95% CI 19-46) compared with 17 days (95% CI 12-21) for fCDI patients; P = 0.0259. ICU length of stay was also longer for rCDI patients than for fCDI patients (mean 2.5 versus 0.7 days). Mean total variable costs for fCDI and rCDI were £2382 (95% CI 1750-3014) and £4683 (95% CI 3051-6311), respectively; P = 0.009. Mean fixed costs for fCDI and rCDI were £10 328 (95% CI 7555-13 101) and £26 438 (95% CI 16 135-36 742), respectively; P = 0.003. Mean total costs for fCDI and rCDI were £12 710 (95% CI 9652-15 769) and £31 121 (95% CI 19 792-42 447), respectively; P < 0.002.

CONCLUSIONS

The healthcare resource use and financial burden attributable to CDI is significant. Most excess cost is driven by additional length of hospital stay. These costs may have been underestimated in previous studies that have not accounted for several difficult-to-measure parameters or have used averaged tariff-based estimates.

摘要

目的

目前缺乏关于艰难梭菌感染(CDI)经济负担的准确且足够详细的数据。我们进行了一项微观成本研究,以确定首次发作艰难梭菌感染(fCDI)和再次发作艰难梭菌感染(rCDI)患者的卫生资源利用情况。

患者和方法

通过年龄、性别和诊断日期,对 45 例 rCDI 成年和儿科住院患者与 fCDI 对照患者进行了匹配。测量并比较了两组患者的总住院时间、重症监护病房(ICU)住院时间和几个成本参数,这些参数分为固定和可变两部分。

结果

rCDI 患者的平均总住院时间为 33 天(95%置信区间 19-46),而 fCDI 患者为 17 天(95%置信区间 12-21);P=0.0259。rCDI 患者的 ICU 住院时间也长于 fCDI 患者(平均 2.5 天对 0.7 天)。fCDI 和 rCDI 的总可变成本分别为 2382 英镑(95%置信区间 1750-3014)和 4683 英镑(95%置信区间 3051-6311);P=0.009。fCDI 和 rCDI 的固定成本分别为 10328 英镑(95%置信区间 7555-13101)和 26438 英镑(95%置信区间 16135-36742);P=0.003。fCDI 和 rCDI 的总费用分别为 12710 英镑(95%置信区间 9652-15769)和 31121 英镑(95%置信区间 19792-42447);P<0.002。

结论

艰难梭菌感染导致的医疗资源使用和经济负担巨大。大部分额外费用是由住院时间延长引起的。这些成本可能在之前的研究中被低估了,因为这些研究没有考虑到一些难以衡量的参数,或者使用了基于平均费用的估计。

相似文献

1
Healthcare resource use and attributable cost of Clostridium difficile infection: a micro-costing analysis comparing first and recurrent episodes.艰难梭菌感染的医疗资源利用和可归因成本:比较首次和复发性发作的微观成本分析。
J Antimicrob Chemother. 2018 Oct 1;73(10):2851-2855. doi: 10.1093/jac/dky250.
2
Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life.复发性艰难梭菌感染的影响:住院和患者生活质量。
J Antimicrob Chemother. 2017 Sep 1;72(9):2647-2656. doi: 10.1093/jac/dkx174.
3
Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States.美国原发性和复发性艰难梭菌感染患者的医疗资源利用和成本归因分析。
Clin Infect Dis. 2018 Apr 17;66(9):1326-1332. doi: 10.1093/cid/cix1021.
4
Healthcare resource utilization and direct medical costs associated with index and recurrent infection: a real-world data analysis.与首发和复发感染相关的医疗资源利用和直接医疗成本:真实世界数据分析。
J Med Econ. 2020 Jun;23(6):603-609. doi: 10.1080/13696998.2020.1724117. Epub 2020 Feb 13.
5
Predictors and burden of hospital readmission with recurrent Clostridioides difficile infection: a French nation-wide inception cohort study.复发性艰难梭菌感染患者的住院再入院预测因素和负担:一项法国全国性的发病队列研究。
Eur J Clin Microbiol Infect Dis. 2019 Jul;38(7):1297-1305. doi: 10.1007/s10096-019-03552-9. Epub 2019 Apr 2.
6
Healthcare burden of recurrent Clostridioides difficile infection in Japan: A retrospective database study.日本复发性艰难梭菌感染的医疗负担:一项回顾性数据库研究。
J Infect Chemother. 2018 Nov;24(11):892-901. doi: 10.1016/j.jiac.2018.07.020. Epub 2018 Sep 3.
7
Health care resource utilization and costs of recurrent infection in the elderly: a real-world claims analysis.老年人反复感染的医疗资源利用情况及成本:一项真实世界索赔分析。
J Manag Care Spec Pharm. 2021 Jul;27(7):828-838. doi: 10.18553/jmcp.2021.20395. Epub 2021 Mar 11.
8
Excess length of hospital stay, mortality and cost attributable to () infection and recurrence: a nationwide analysis in Japan.()感染和复发导致的住院时间延长、死亡率和费用:日本全国性分析。
Epidemiol Infect. 2020 Mar 2;148:e65. doi: 10.1017/S0950268820000606.
9
Recurrent Clostridium difficile infection in intensive care unit patients.重症监护病房患者复发性艰难梭菌感染
Am J Infect Control. 2016 Jan 1;44(1):36-40. doi: 10.1016/j.ajic.2015.08.013. Epub 2015 Oct 1.
10
Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study.住院患者中初次与复发性艰难梭菌感染的经济负担:一项前瞻性队列研究。
J Hosp Infect. 2016 Jul;93(3):286-9. doi: 10.1016/j.jhin.2016.04.004. Epub 2016 Apr 20.

引用本文的文献

1
Case Series: Efficacy of Polyclonal Intravenous Immunoglobulin for Refractory Infection.病例系列:多克隆静脉注射免疫球蛋白治疗难治性感染的疗效
Antibodies (Basel). 2024 Apr 1;13(2):26. doi: 10.3390/antib13020026.
2
Economic Burden of Clostridioides difficile Infection in European Countries.欧洲国家艰难梭菌感染的经济负担。
Adv Exp Med Biol. 2024;1435:1-12. doi: 10.1007/978-3-031-42108-2_1.
3
Improving care for patients with infection: A clinical practice and healthcare systems perspective.改善感染患者的护理:临床实践与医疗保健系统视角
Front Med (Lausanne). 2023 Jan 12;9:1033417. doi: 10.3389/fmed.2022.1033417. eCollection 2022.
4
Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection.非达霉素与万古霉素或甲硝唑用于艰难梭菌感染住院治疗的真实世界预算影响
Antibiotics (Basel). 2023 Jan 6;12(1):106. doi: 10.3390/antibiotics12010106.
5
Biofilm regulation in Clostridioides difficile: Novel systems linked to hypervirulence.艰难梭菌生物膜调控:与强毒力相关的新型系统。
PLoS Pathog. 2021 Sep 9;17(9):e1009817. doi: 10.1371/journal.ppat.1009817. eCollection 2021 Sep.
6
A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany.从德国医院管理角度出发,对 bezlotoxumab 与仅使用标准护理抗生素相比用于高复发性 CDI 风险患者的预算影响分析。
BMC Health Serv Res. 2021 Sep 9;21(1):939. doi: 10.1186/s12913-021-06970-8.
7
Economic burden of recurrent Clostridioides difficile infection in adults admitted to Spanish hospitals. A multicentre retrospective observational study.西班牙医院成人复发性艰难梭菌感染的经济负担:一项多中心回顾性观察研究。
Rev Esp Quimioter. 2021 Apr;34(2):126-135. doi: 10.37201/req/135.2020. Epub 2021 Feb 23.
8
Economic evaluation of Faecal microbiota transplantation compared to antibiotics for the treatment of recurrent infection.粪菌移植与抗生素治疗复发性感染的经济学评估
EClinicalMedicine. 2020 Jun 27;24:100420. doi: 10.1016/j.eclinm.2020.100420. eCollection 2020 Jul.
9
Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.贝洛妥珠单抗 MODIFY I 和 II 临床试验中欧洲参与者艰难梭菌感染相关结局分析。
Eur J Clin Microbiol Infect Dis. 2020 Oct;39(10):1933-1939. doi: 10.1007/s10096-020-03935-3. Epub 2020 Jun 6.
10
Cost savings following faecal microbiota transplantation for recurrent infection.粪便微生物群移植治疗复发性感染后的成本节约
Therap Adv Gastroenterol. 2019 Apr 10;12:1756284819843002. doi: 10.1177/1756284819843002. eCollection 2019.